Special Issue

State-of-the-Art HIV and HTLV Research in Latin America

Message from the Guest Editors

HTLV infection is frequently detected in some areas of the world. In Latin America, several countries have documented endemic areas. To date, there is no specific treatment for HTLV infection, and many aspects of the infection remain obscure. HIV infection is also endemic in Latin American countries, and despite increasing access to antiretroviral therapy, there are still many new infections and deaths caused by HIV every year. Coinfection by HIV and HTLV is also a frequent finding, and its consequences can be reciprocal. This Special Issue will focus on different aspects of HTLV and HIV infections in Latin America. Epidemiological data, interaction with other infectious diseases, prognostic biomarkers, therapeutic approaches, and aspects of immune response are points of interest. In addition, any relevant information on the results of such problems will be also welcome. We will encourage reports on all information potentially relevant to Latin American countries.

Guest Editors

Prof. Dr. Carlos Brites

Department of Internal Medicine, School of Medicine, Federal University of Bahia, Salvador, BA, Brazil

Prof. Dr. Antonio Vallinoto

Laboratory of Virology, Institute of Biological Sciences, Federal University of Pará (UFPA), Belém 66075-110, PA, Brazil

Deadline for manuscript submissions

closed (15 November 2023)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/113473

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

